Quality-of-life and treatment satisfaction in actual clinical practice of patients with Type 1 diabetes mellitus (T1DM) and hypoglycemia treated with insulin degludec

References

• Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care 2004;27:1218-24
   PubMed Web of Science ®Google Scholar
• Gomis R, Herrera-Pombo JL, Calderón A, et al. Validación del cuestionario “Diabetes treatment satisfaction questionnaire” (DTSQ) en la población española. Pharmacoeconomics -Spanish Res Artic 2006;3:7-18
   Google Scholar
• Imayama I, Plotnikoff RC, Courneya KS, et al. Determinants of quality of life in adults with type 1 and type 2 diabetes. Health Qual Life Outcomes 2011;9:115
   PubMed Web of Science ®Google Scholar
• Saito I, Inami F, Ikebe T, et al. Impact of diabetes on health-related quality of life in a population study in Japan. Diabetes Res Clin Pract 2006;73:51-7
   PubMed Web of Science ®Google Scholar
• Katz JN. Patient preferences and health disparities. JAMA 2001;286:1506-9
   PubMed Web of Science ®Google Scholar
• Khunti K, Alsifri S, Aronson R, et al. Rates and predictors of hypoglycaemia in 27 585 people from 24 countries with insulin-treated type 1 and type 2 diabetes: the global HAT study. Diabetes Obes Metab 2016;18:907-15
   PubMed Web of Science ®Google Scholar
• Geddes J, Schopman JE, Zammitt NN, et al. Prevalence of impaired awareness of hypoglycaemia in adults with Type 1 diabetes. Diabet Med 2008;25:501-4
   PubMed Web of Science ®Google Scholar
• Currie CJ, Morgan CL, Poole CD, et al. Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Curr Med Res Opin 2006;22:1523-34
   PubMed Web of Science ®Google Scholar
• Rubin RR, Peyrot M. Psychological issues and treatments for people with diabetes. J Clin Psychol 2001;57:457-78
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Dailey G, Massi-Benedetti M, et al. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care 2005;28:950-5
   PubMed Web of Science ®Google Scholar
• Vajo Z, Fawcett J, Duckworth WC. Recombinant DNA technology in the treatment of diabetes: insulin analogs. Endocr Rev 2001;22:706-17
   PubMed Web of Science ®Google Scholar
• Wang F, Surh J, Kaur M. Insulin degludec as an ultralong-acting basal insulin once a day: a systematic review. Diabetes, Metab Syndr Obes Targets Ther 2012;5:191-204
   PubMedGoogle Scholar
• Gough SCL, Harris S, Woo V, et al. Insulin degludec: overview of a novel ultra long-acting basal insulin. Diabetes Obes Metab 2013;15:301-9
   PubMed Web of Science ®Google Scholar
• Home PD, Meneghini L, Wendisch U, et al. Improved health status with insulin degludec compared with insulin glargine in people with Type 1 diabetes. Diabet Med 2012;29:716-20
   PubMed Web of Science ®Google Scholar
• Freemantle N, Meneghini L, Christensen T, et al. Insulin degludec improves health-related quality of life (SF-36®) compared with insulin glargine in people with Type 2 diabetes starting on basal insulin: a meta-analysis of phase 3a trials. Diabet Med 2013;30:226-32
   PubMed Web of Science ®Google Scholar
• Mannucci E, Monami M, Dicembrini I, et al. Achieving HbA1c targets in clinical trials and in the real world: a systematic review and meta-analysis. J Endocrinol Invest 2014;37:477-95
   PubMed Web of Science ®Google Scholar
• Depablos-Velasco P, Salguero-Chaves E, Mata-Poyo J, et al. Calidad de vida y satisfacción con el tratamiento de sujetos con diabetes tipo 2: resultados en España del estudio panorama. Endocrinol Nutr 2014;61:18-26
   PubMed Web of Science ®Google Scholar
• Gonder-Frederick LA, Schmidt KM, Vajda KA, et al. Psychometric properties of the hypoglycemia fear survey-ii for adults with type 1 diabetes. Diabetes Care 2011 Apr;34(4):801-6
   PubMed Web of Science ®Google Scholar
• Herdman M, Badia X, Berra S. [EuroQol-5D: a simple alternative for measuring health-related quality of life in primary care]. Aten Primaria 2001;28:425-30
   PubMedGoogle Scholar
• Home PD, Meneghini L, Wendisch U, et al. Improved health status with insulin degludec compared with insulin glargine in people with Type1 diabetes. Diabet Med 2012 Jun;29(6):716-20
   PubMed Web of Science ®Google Scholar
• Grandy S, Langkilde AM, Sugg JE, et al. Health-related quality of life (EQ-5D) among type 2 diabetes mellitus patients treated with dapagliflozin over 2 years. Int J Clin Pract 2014 Apr;68(4):486-94
   PubMed Web of Science ®Google Scholar
• Bradley C. Diabetes treatment satisfaction questionnaire. Change version for use alongside status version provides appropriate solution where ceiling effects occur. Diabetes Care 1999;22:530-2
   PubMed Web of Science ®Google Scholar
• Galasso S, Facchinetti A, Bonora BM, et al. Switching from twice-daily glargine or detemir to once-daily degludec improves glucose control in type 1 diabetes. An observational study. Nutr Metab Cardiovasc Dis 2016;26:1112-19
   PubMed Web of Science ®Google Scholar
• Heise T, Hövelmann U, Nosek L, et al. Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine. Expert Opin Drug Metab Toxicol 2015;11:1193-201
   PubMed Web of Science ®Google Scholar
• Landstedt-Hallin L, Phd M. Current Medical Research and Opinion Brief report. Changes in HbA 1c, insulin dose and incidence of hypoglycemia in patients with type 1 diabetes after switching to insulin degludec in an outpatient setting: an observational study. Curr Med Res Opin Cit Curr Med Res Opin 2015 Aug;31(8):1487-93
   PubMed Web of Science ®Google Scholar
• Evans M, McEwan P, Foos V. Insulin degludec early clinical experience: does the promise from the clinical trials translate into clinical practice—a case-based evaluation. J Med Econ 2015;18:96-105
   PubMed Web of Science ®Google Scholar
• Shimoda S, Sato M, Sekigami T, et al. A 1-year, prospective, observational study of Japanese outpatients with type 1 and type 2 diabetes switching from insulin glargine or detemir to insulin degludec in basal-bolus insulin therapy (Kumamoto Insulin Degludec Observational study). J Diabetes Investig 2016;7:703-10
   PubMed Web of Science ®Google Scholar
• Evans M, Wolden M, Gundgaard J, et al. Cost-effectiveness of insulin degludec compared with insulin glargine for patients with type 2 diabetes treated with basal insulin - from the UK health care cost perspective. Diabetes Obes Metab 2014;16:366-75
   PubMed Web of Science ®Google Scholar
• Evans M, Chubb B, Gundgaard J. Cost-effectiveness of insulin degludec versus insulin glargine in adults with type 1 and type 2 diabetes mellitus. Diabetes Ther 2017;8:275-91
   PubMed Web of Science ®Google Scholar
• Mezquita-Raya P, Darbà J, Ascanio M, et al. Cost-effectiveness analysis of insulin degludec compared with insulin glargine u100 for the management of type 1 and type 2 diabetes mellitus – from the Spanish National Health System perspective. Expert Rev Pharmacoecon Outcomes Res 2017;17:587-95
   PubMed Web of Science ®Google Scholar
• Landstedt-Hallin L. Changes in HbA1c, insulin dose and incidence of hypoglycemia in patients with type 1 diabetes after switching to insulin degludec in an outpatient setting: an observational study. Curr Med Res Opin 2015;31:1487-93
   PubMed Web of Science ®Google Scholar
• Kusunoki Y, Katsuno T, Miyakoshi K, et al. Effects of switching from insulin glargine or detemir to insulin degludec in patients with type 1 diabetes mellitus. Diabetes Ther 2013 Dec;4(2):461-72
   PubMed Web of Science ®Google Scholar
• Merchante-Alfaro AÁ, Pérez-Naranjo S, Abellán-Galiana P, et al. Insulin degludec: the new standard long acting insulin analogue for people with type 1 diabetes? [Letter to the Editor]. Endocr J 2016;63:411-12
   PubMed Web of Science ®Google Scholar
• Shimoda S, Sato M, Sekigami T, et al. A 1-year, prospective, observational study of Japanese outpatients with type 1 and type 2 diabetes switching from insulin glargine or detemir to insulin degludec in basal-bolus insulin therapy (Kumamoto Insulin Degludec Observational study). J Diabetes Investig 2016;7:703-10
   PubMed Web of Science ®Google Scholar
• Okada M, Okada M, Nishigami J, et al. Effect of switching basal insulin regimen to degludec on quality of life in Japanese patients with type 1 and type 2 diabetes mellitus. J Pharm Heal Care Sci 2015;1:26
   PubMed Web of Science ®Google Scholar
• Lajara R, Cengiz E, Tanenberg RJ. The role of the new basal insulin analogs in addressing unmet clinical needs in people with type 1 and type 2 diabetes. Curr Med Res Opin 2017 Jun;33(6):1045-1055
   PubMed Web of Science ®Google Scholar
• Freemantle N, Evans M, Christensen T, et al. A comparison of health-related quality of life (health utility) between insulin degludec and insulin glargine: a meta-analysis of phase 3 trials. Diabetes Obes Metab 2013 Jun;15(6):564-71
   PubMed Web of Science ®Google Scholar
• Kaku K, Eid MA. Safety, efficacy, and early clinical experience of insulin degludec in Japanese people with diabetes mellitus: a first-year report from Japan. J Diabetes Investig 2015;6:610-19
   PubMed Web of Science ®Google Scholar